Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality

To investigate the effect of chronic comorbidity on the time of diagnosis of multiple sclerosis (MS) and on mortality in MS. We conducted a population-based, nationwide cohort study including all incident MS cases in Denmark with first MS symptom between 1980 and 2005. To investigate the time of dia...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neurology Ročník 89; číslo 16; s. 1668
Hlavní autoři: Thormann, Anja, Sørensen, Per Soelberg, Koch-Henriksen, Nils, Laursen, Bjarne, Magyari, Melinda
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 17.10.2017
Témata:
Adult
Autoimmune Diseases - epidemiology
Cardiovascular Diseases - epidemiology
Cerebrovascular Disorders - epidemiology
Cohort Studies
Community Health Planning
Comorbidity
Delayed Diagnosis - mortality
Denmark - epidemiology
Female
Humans
Kidney Diseases - epidemiology
Logistic Models
Male
Middle Aged
Mood Disorders - epidemiology
Multiple Sclerosis - diagnosis
Multiple Sclerosis - epidemiology
Multiple Sclerosis - mortality
Neoplasms - epidemiology
Neurologic Examination
Parkinson Disease - epidemiology
Time Factors
Young Adult
ISSN:1526-632X, 1526-632X
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:To investigate the effect of chronic comorbidity on the time of diagnosis of multiple sclerosis (MS) and on mortality in MS. We conducted a population-based, nationwide cohort study including all incident MS cases in Denmark with first MS symptom between 1980 and 2005. To investigate the time of diagnosis, we compared individuals with and without chronic comorbidity using multinomial logistic regression. To investigate mortality, we used Cox regression with time-dependent covariates, following study participants from clinical MS onset until endpoint (death) or to the end of the study, censuring at emigration. We identified 8,947 individuals with clinical onset of MS between 1980 and 2005. In the study of time of diagnosis, we found statistically significant odds ratios for longer diagnostic delays with cerebrovascular comorbidity (2.01 [1.44-2.80]; <0.0005), cardiovascular comorbidity (4.04 [2.78-5.87]; <0.0005), lung comorbidity (1.93 [1.42-2.62]; <0.0005), diabetes comorbidity (1.78 [1.04-3.06]; 0.035), and cancer comorbidity (2.10 [1.20-3.67]; 0.009). In the mortality study, we found higher hazard ratios with psychiatric comorbidity (2.42 [1.67-3.01]; <0.0005), cerebrovascular comorbidity (2.47 [2.05-2.79]; <0.0005), cardiovascular comorbidity (1.68 [1.39-2.03]; <0.0005), lung comorbidity (1.23 [1.01-1.50]; 0.036), diabetes comorbidity (1.39 [1.05-1.85]; 0.021), cancer comorbidity (3.51 [2.94-4.19]; <0.0005), and Parkinson disease comorbidity (2.85 [1.34-6.06]; 0.007). An increased awareness of both the necessity of neurologic evaluation of new neurologic symptoms in persons with preexisting chronic disease and of optimum treatment of comorbidity in MS is critical.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1526-632X
1526-632X
DOI:10.1212/WNL.0000000000004508